COVID-19 Vaccine Booster Trial Blinded Elixir from Canada
Blinded liquid elixir placebo for oral intake in Phase IV COVID-19 booster trials, in 10ml sachets mimicking vaccine adjuvant taste profile. Falls under HTS 3006.93.60.00 as double-blinded clinical trial material in measured oral doses.
Duty Rate — Canada → United States
100%
Rate breakdown
9903.04.60100%Pharmaceuticals Annex IV: patented pharma articles — 100% floor rate
9903.05.860%Universal product exemption (U.S. note 52(b))
9903.05.900%Articles already subject to Section 232 (steel/aluminum/copper + derivatives, autos + parts, wood, medium/heavy vehicles + parts, semiconductors, patented pharma) — U.S. note 52(f)
Import Tips
• Provide emergency use authorization or IND linked to public health emergency trials for expedited clearance
• Label with trial phase and sponsor to distinguish from waste pharmaceuticals under 3006(k)
• Test for alcohol content if any, to avoid Chapter 22 reclassification